Abstract: An application of a skeletal muscle secreted factor Thbs4 in a preparation of a drug for improving systemic glucose and lipid metabolism is provided. According to the present invention, it is found through experiments that Thbs4 increases a body's metabolic rate by activating a beige-like change of white adipose, relieves the metabolic disorder caused by high-fat diet, and reveals its application value in the treatment of the metabolic disorder.

Abstract: Disclosed herein are methods and compositions for prognosing or diagnosing an obstructive renal dysfunction or ureteropelvic junction obstruction (UPJO) in a subject, involving detecting in a urine sample from a subject one or more proteins selected from the group consisting of Immunoglobulin superfamily containing leucine-rich repeat protein (ISLR); Nicotinate-nucleotide pyrophosphorylase [carboxylating] (QPRT); Prostaglandin reductase 1 (PTGR1); Vascular cell adhesion protein 1 (VCAM1); and Ficolin-2 (FCN2), or detectable portions thereof to identify the subject as at risk of or having an obstructive renal dysfunction or UPJO.

Abstract: The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

Abstract: The subject matter of the present disclosure generally relates to techniques for following a treatment protocol having one or more treatment parameters to cause a targeted physiological outcome at a distal site, assessing an expression level of a gene in a region of interest after completing the treatment protocol, and modifying the one or more treatment parameters based on the expression level of the gene. The treatment protocol may include one or more ultrasound energy treatments to the region of interest.

Abstract: This document provides methods and materials involved in assessing and/or treating a mammal having a functional gastrointestinal disorder (FGID) such as irritable bowel syndrome (IBS). For example, methods and materials provided herein can be used for determining if a mammal having a FGID is likely to respond to a particular FGID treatment. This document also provides methods and materials for treating a mammal having a FGID.

Abstract: Provided herein are methods of diagnosing and monitoring disease activity and response to treatment in patients having systemic lupus erythematosus using panels of biomarkers, such as at least one biomarker selected from the group consisting of B-lymphocyte-bound C4d, erythrocyte-bound C4d, platelet-bound C4d, and erythrocyte complement receptor type 1, and one further biomarker selected from the group consisting of anti-MCV antibody and anti-nuclear antibody.

Abstract: Devices that include a low sensitivity bulk acoustic wave (BAW) resonator sensor including a surface to which a low recognition component is immobilized, the low recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; a high sensitivity BAW resonator sensor including a surface to which a high recognition component is immobilized, the high recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; one or more containers housing an amplification molecule, the amplification element-linked second recognition component, and optionally one or both of the tag and the analyte molecule.

Abstract: A system for monitoring gluten consumption, especially in celiac people, which allows the feeding of food consumption data and updating, in real time, of the estimated amount of gluten consumed daily. Still, the present invention refers to a system for prediction that associates the possibility of an indisposition being associated or not with an undue consumption of gluten.

Abstract: A method of creating an isogenic multicellular blood-brain barrier model from iPSCs is disclosed.

Abstract: Methods, systems and techniques for the accurate measurement of breath-borne biomarkers are disclosed. Such methods, systems and techniques may be used for the purposes of detection and/or measurement in breath samples of biomarkers, e.g., biomarkers relating to a disease or a physiological condition.

Abstract: A method of making a plasmon-resonance biosensor includes conjugating precious metal nanorods with form factor at least 1.5 with a biological probe material. Microfluidic chambers of volume under 0.025 microliter are formed over a substrate, and an aqueous suspension of the conjugated nanorods is injected into the chambers. The nanorods are organized in rows and aligned in long dimension along the rows. The biosensor is configured to be read by obtaining an optical absorption spectrum upon exposure to the analyte. The biosensor includes precious metal nanorods organized in rows with long dimension approximately parallel to the rows. The nanorods are conjugated with biological probes capable of binding to an analyte, the probes may be an aptamer, an antibody, a protein-nucleic acid (PNA), a complimentary DNA, or an enzyme having a binding site.

Abstract: The invention relates to novel methods, uses and compositions for the prophylaxis or the treatment of osteoarthritis, and conditions associated therewith.

Abstract: Provided herein is a method for predicting the probability of having or developing a non-fusion, wherein said method comprises determining the frequency of a subpopulation of CD8+ T cells selected from CD8+CD57+, CD8+CD28? and CD8+CD57+CD28? in a sample obtained from a patient. Also provided herein is a system for predicting the probability of having or developing a non-fusion.

Abstract: This invention provides a method for diagnosis of rheumatoid arthritis of a subject, a method for assisting diagnosis of rheumatoid arthritis, and a method for monitoring disease activity of rheumatoid arthritis and/or therapeutic effects of an agent for rheumatoid arthritis, comprising detecting citrullination of an arginine residue of the inter-?-trypsin inhibitor heavy chain (ITIH) 4 in a biological sample obtained from the subject. This invention also provides a citrullinated protein derived from the protein having the amino acid sequence as shown in SEQ ID NO: 1 or 5 by modification of arginine 438 into citrulline or a fragment thereof, an antibody binding to such citrullinated protein, and an agent for diagnosis of rheumatoid arthritis comprising such antibody.

Abstract: Pink noise analysis, along with unique properties of the photovoltaic (PV) operating point of both the instantaneous current and voltage signal, is used to distinguish arc faults from other noisy loads or PV degradations.

Abstract: Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury The methods use assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, SIOO-AI2, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-I receptor antagonist, Interleukin-I beta, lnterleukun-10, lnterieukun-15, lnterieukun-3, Myeloperoxidase, Nidogen-I, soluble Oxidized low-density lipoprotein receptor I, Pappalysin-I, soluble P-selectin glycoprotein ligand I, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinasel, Tissue inhibitor of metalloproteinase 2, soluble Tumor n

Abstract: A method of in vitro cellular assay includes measuring an electrical activity of at least two cell populations in a plurality of cell populations that are disposed to be spaced apart from each other and connected to each other via a neurite, in which at least one of the at least two cell populations for which the electrical activity is measured is a cell population including at least one kind of neural cell, and the at least two cell populations each exhibit different electrical activity properties at a point when the electrical activity is measured.

Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.

Abstract: Methods of sequencing a protein using a novel digestion-on-emitter technology are provided.

Abstract: The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.

Abstract: Examples pertaining to detection of radio resource control (RRC) reestablishment without reconfiguration in mobile communications. An apparatus reestablishes a RRC connection with a wireless network. The apparatus then detects whether a type of radio bearer service is resumed upon reestablishing the RRC connection. In response to detecting that the type of radio bearer service is not resumed, the apparatus resumes the type of radio bearer service.

Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.

Abstract: Methods for testing a red blood cell (RBC) unit for release for transfusion into a subject are described. The methods allow management of the blood supply by assessing the viability of an RBC unit by its levels of dicarboxylic fatty acids (DFA). The methods include testing an RBC sample from an RBC unit for levels of DFA and discarding the RBC unit or releasing or not releasing the RBC unit for transfusion based on the results.

Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.

Abstract: Water soluble light harvesting multichromophores that have an ultraviolet absorption maximum are provided. In some embodiments, the multichromophores include a conjugated segment including a fused 6-5-6 tricyclic co-monomer and a UV absorbance-modifying co-monomer. The multichromophores may include an acceptor chromophore covalently linked to the multichromophore in energy-receiving proximity therewith. In some embodiments, a specific binding member is covalently linked to the multichromophore. Also provided are methods of evaluating a sample for the presence of a target analyte and methods of labelling a target molecule using compositions including the light harvesting multichromophores. Kits and systems for practicing the subject methods are also provided.

Abstract: Methods and kits for sampling mucous from within a sinus to determine if a single sample includes one or more bacterial types indicating a bacterial infection, such as bacterial sinusitis, and one or more viruses indicating a viral infection, such as influenza.

Abstract: The disclosure concerns a method and a device for enriching cells, cell fragments and molecules from whole blood for a specific detection of at least one population of cells, cell fragments or molecules contained therein. The task was to detect a broad spectrum of target objects including their molecules simply, quickly and yet sensitively and specifically from whole blood. According to the disclosure, not the target objects themselves, but matrix objects are specifically enriched, but target objects are specifically analyzed and thus a specific and sensitive detection of target objects is achieved.

Abstract: A method for determining in a sample, by mass spectrometry, the amount of one or more analytes selected from the group consisting of N-acetylthreonine, TMAP, phenylacetylglutamine, tryptophan, creatinine, meso-erythritol, arabitol, myo-inositol, N-acetyl serine, N-acetylalanine, 3-methylhistidine, trans-4-hydroxyproline, kynurenine, urea, C-glycosyltryptophan, 3-indoxyl sulfate, pseudouridine, and combinations thereof is described. The method comprises subjecting the sample to an ionization source under conditions suitable to produce one or more ions detectable by mass spectrometry from each of the one or more of the analytes; measuring, by mass spectrometry, the amount of the one or more ions from each of the one or more analytes; and using the measured amount of the one or more ions to determine the amount of each of the one or more analytes in the sample. Also described is a kit comprising one or more isotopically labeled analogues as internal standards for each of the one or more analytes.

Abstract: The present disclosure relates generally to conformation-specific antibodies that can bind to and neutralize the activity of phosphorylated-Threonine 231-tau protein (pT231-tau). The antibodies of the present technology are useful in methods for treating a neurological disorder associated with elevated cis-pT231-tau protein expression in a subject in need thereof.

Abstract: The invention provides gastroenterological cancer determination methods that involve contacting a specimen, an antibody 1 that recognizes an ? chain of human haptoglobin, and an antibody 2 that recognizes a ? chain of human haptoglobin and does not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 1, or contacting the specimen and two antibodies selected from the antibodies 2 that recognize a ? chain of human haptoglobin and do not recognize human haptoglobin in which an S—S bond is cleaved to form a complex 2. A determination is made based on the measurement of complex 1 or 2. Alternatively, the specimen and two antibodies selected from the antibodies 1 that recognize an ? chain of human haptoglobin are contacted to form a complex 3, and a determination is made by comparing the measurement results of complex 1 or 2 with complex 3.

Abstract: Methods for diagnosing a subject as a candidate for removal of a solid tumor without preoperative chemoradiation therapy, and methods for treating patients having solid tumors, who have one or more of genomic instability, elevated double stranded DNA breaks, elevated gamma-H2AX foci, or elevated replication stress and/or double stranded break-signalling (DSB-signalling) biomarkers in peripheral blood lymphocytes (PBLs) are provided herein.

Abstract: Methods and systems directed to monitoring for the presence or progression of amyloid diseases via detection of amyloid fibrils in a sample from an individual are disclosed. An individual, or sample from an individual, is treated with a reagent including a fluorescent protein. The fluorescent protein in the reagent binds to amyloid fibrils present in the sample. Detecting a signal from fluorescent protein bound to the treated sample indicates the presence of amyloid fibrils in the sample and possible diagnosis of an amyloid disease. The presence and progression of an amyloid disease is monitored by quantifying signal intensity from samples taken over time. Treatment with a reagent including a fluorescent protein inhibits amyloid fibril formation by providing the reagent to an environment including amyloid monomers. The fluorescent protein binds to amyloid oligomers during the lag phase and/or elongation phase of amyloid fibril formation, preventing formation of mature amyloid fibrils.

Abstract: Certain aspects of the present disclosure generally relate to systems and methods for determining viruses such as coronaviruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, free RNA or other nucleic acids may preferentially partition into one phase, while intact viruses may be present in the other phase or in both phases. Accordingly, in some cases, free RNA or other nucleic acids may be preferentially removed, e.g., as compared to intact RNA or other nucleic acids present within a virus. In some cases, the phase containing intact viruses can be determined to determine the infectiousness, e.g., of a sample arising from a subject. This may be useful, for example, for distinguishing subjects who are capable of spreading an infection from those who are not infectious.

Abstract: The present invention provides methods for analysing a urine sample from a subject comprising exposing the urine sample to a lysis buffer which is capable of releasing at least one biomarker from cells in the urine sample. The present invention further provides kits, devices, and apparatuses that can be used in these methods. Finally, the present invention provides methods for detecting the presence of a urological cancer in a subject comprising performing an assay on a sample from a subject to determine the concentration of an Mcm protein.

Abstract: A method for finding manufactured or to-be-manufactured products for defects includes obtaining basic information on processing history of products passed by each manufacturing machine at each processing workstation, and obtaining processing factor information of same, where each product is passed by a defect detection workstation after the product is passed by at least one processing workstation. The method includes obtaining quality information detected by each defect detection workstation. The method determines one or more problem manufacturing machines at one or more problem processing workstations according to the basic information on processing history and the quality information of the products. The method further determines one or more processing factors which influence the problem manufacturing machines according to the processing factor information of each manufacturing machine and the quality information of the products.

Abstract: Systems and methods are provided for improving skincare product formulations to address predicted skin trends. A biomarker analysis system is used to determine concentrations of various protein biomarkers of a user. A skin diagnosis computing device uses the protein biomarker concentrations to determine one or more skin trends, and determines one or more skincare product ingredients to address the skin trends. A skincare product is compounded that includes the one or more skincare product ingredients.

Abstract: Provided is a method for evaluating the progression of glioma in an individual comprising monitoring the levels of circulating exosomes that are positive for survivin and a glial marker (such as glial fibrillary acidic protein). An increase in the level of such exosomes is indicative of poor prognosis. Levels of circulating exosomes that are positive for survivin and glial marker can also be used for evaluating the efficacy of a therapy for glioma in an individual, and modifying the therapy or introducing additional therapy if levels of such exosomes are found to be increasing.

Abstract: Magnetic beads having cell components of interest are translated between a sequence of processing wells in a tray without need for pipetting. The circular tray contains one or more sequences of wells each interconnected by a respective channel. The tray is rotated about a central axis and a magnet, an agitator, and a heater provided external to the tray enable magnetic bead translation, mixing, and incubation, respectively. The magnet proximate a well forms a cluster of beads. Manipulation of the tray in rotation and elevation results in translation of the cluster from one well, through a channel, and into an adjacent well. The well containing a cluster may be rotationally positioned in front of the agitator, the agitator extended into contact with the well, followed by mechanical agitation. The heater, disposed beneath the tray, may accept a well lowered thereto for selective heating.

Abstract: The present invention provides human bone-marrow cells enriched with functional mitochondria, methods for their production, and therapeutic methods utilizing such cells.

Abstract: The invention relates to the field of medical diagnostics. Provided are methods and kits for determining the health status of a subject, for early detection of tissue damage, for early diagnosis and monitoring of a disease, and/or for evaluation of treatment effectiveness in a subject using circulating tissue macrophages (CTM) as a mirror of disrupted tissue homeostasis and disease.

Abstract: Various systems and methods for predicting metabolic and bariatric surgery outcomes are provided. The systems and methods can also provide predictions for non-surgical metabolic and bariatric treatments. In general, a user can receive predictive outcomes of multiple bariatric procedures that could be performed on a patient. In one embodiment, a user can electronically access a metabolic and bariatric surgery outcome prediction system, e.g., using one or more web pages. The system can provide predictive outcomes of one or more different bariatric surgeries for the patient based on data gathered from the user and on historical data regarding outcomes of the different bariatric surgeries. The system can additionally provide predictive outcomes for not having any treatment and/or a comparison of the predictive outcomes of the one or more different bariatric surgeries to the predictive outcomes for not having any treatment.

Abstract: A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.

Abstract: The described invention provides an ex vivo dynamic multiple myeloma cancer niche contained in a pumpless perfusion culture device. The dynamic multiple myeloma cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the bone marrow niche, and the viability of the human myeloma cells is maintained by the multiple myeloma cancer niche.

Abstract: Devices that include a low sensitivity bulk acoustic wave (BAW) resonator sensor including a surface to which a low recognition component is immobilized, the low recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; a high sensitivity BAW resonator sensor including a surface to which a high recognition component is immobilized, the high recognition component being configured to selectively bind the analyte, an analyte molecule to which a tag is linked, or a tag, or any one of these molecules to which an amplification element-linked second recognition component is bound; one or more containers housing an amplification molecule, the amplification element-linked second recognition component, and optionally one or both of the tag and the analyte molecule.

Abstract: A fluid detection system includes a wicking material to draw fluid away from a first location with space limitations and proximate to a fluid device or a fluid interface. The wicking material draws the fluid to a remote fluid indicator at a second location. Contact between fluid and the remote fluid indicator produces a detectable alteration to the remote fluid indicator, and a non-contact optical sensor detects the alteration.

Abstract: A method for exchange imaging of at least two targets in a sample includes (a) incubating a sample with at least two or more target-recognizing antibodies, each bound to a corresponding monovalent tight antibody binder-docketing moiety (MTAB-DM) reagent capable of binding monovalently to the target-recognizing antibodies, (b) applying at least two imager moieties corresponding to the MTAB-DM, either in series, in batches, or in parallel, and (d) imaging the at least two imager moieties either in series, in batches, or in parallel.

Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.

Abstract: The present invention relates to methods and compositions for quantifying hemoglobin using, inter alia, a peroxidase substrate and hydrogen peroxide.

Abstract: Disclosed herein are caged haptens and caged hapten-antibody conjugates useful for enabling the detection of targets located proximally to each other in a sample.

Abstract: Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.